Privacy Shield Data Privacy Statement

Update on Privacy Shield

In recognition of recent EU court and regulator decisions, Turning Point no longer relies on the EU-U.S. and Swiss-U.S. Privacy Shield Frameworks to legitimize transfers of Personal Information from the EU/Switzerland to the U.S. Despite this, Turning Point remains committed to following robust privacy principles, including those underlying the Privacy Shield frameworks.

Turning Point has certified to the U.S. Department of Commerce that we adhere to the principles underlying the Privacy Shield (the “Principles”). The United States Federal Trade Commission (FTC) has jurisdiction over our compliance with the Privacy Shield and we are subject to the FTC’s investigatory and enforcement powers. Information regarding the Privacy Shield program and evidence of our certification can be found at

Our accountability under the Privacy Shield found by visiting, for the Personal Information we receive and subsequently transfer to third parties is described in the Principles.

In compliance with the Privacy Shield Principles, Turning Point commits to resolve complaints about our collection or use of your personal information. EU and Swiss individuals with inquiries or complaints regarding our Privacy Shield policy should first contact Turning Point at: Turning Point has further committed to cooperate with the panel established by the EU data protection authorities (DPAs) and the Swiss Federal Data Protection and Information Commissioner (FDPIC) with regard to unresolved Privacy Shield complaints concerning data transferred from the EU and Switzerland. If neither Turning Point nor DPAs or FDPIC, as applicable, resolves your complaint, you may have the ability to engage in binding arbitration through the Privacy Shield Panel. Additional information on the arbitration process is available on the Privacy Shield website at

Turning Point Therapeutics is now a
Bristol Myers Squibb company

Select OK for information about Turning Point Therapeutics.

Select BMS to learn more about Bristol Myers Squibb